Two former employees with the California biotech company Amgen Inc. allege the company persuaded sales people to access patient records to boost sales.
The employees allege Amgen officials persuaded them to access patient records and sometimes pose of medical office personnel to influence the prescription of the arthritis and psoriasis drug Enbrel, the Los Angeles Times reported Wednesday.
Federal law prohibits unauthorized access to patient's medical information. Drug companies are also prohibited from marketing off-label uses, though doctors may prescribe drugs for any reason.
A former FDA lawyer said off-label marketing "is if you have a drug for colon cancer that you promote for brain cancer" while another advocate said Amgen violated FDA regulations by persuading patients to seek the Enbrel for milder forms of the diseases it was approved treat.
Copyright 2008 by United Press International
Related stories:
New study proves that pain is not a symptom of arthritis, pain causes arthritis
Pain is more than a symptom of osteoarthritis, it is an inherent and damaging part of the disease itself, according to a study published today in journal
Arthritis and Rheumatism. More specifically, the study revealed that pain signals originating in arthritic joints, and the biochemical processing of those signals as they reach the spinal cord, worsen and expand arthritis. In addition, researchers found that nerve pathways carrying pain signals transfer inflammation from arthritic joints to the spine and back again, causing disease at both ends.
Blood vessel inhibitor shows promise against metastatic thyroid cancer
Thyroid cancer that has spread to distant sites has a poor prognosis, but an experimental drug that inhibits tumor blood vessel formation can slow disease progression in some patients, a research team led by investigators from The University of Texas M. D. Anderson Cancer Center reports in the July 3rd edition of
The New England Journal of Medicine.
Personalized medicine initiative targets lung cancer
A U.S.-based personalized medicine initiative led by scientists from the Biodesign Institute, Translational Genomics Research Institute (TGen) and Seattle’s Fred Hutchinson Cancer Research Center has secured its first major international collaboration with the government of Luxembourg.
Anemia drugs under scrutiny
U.S. drug regulators are contemplating further restrictions on the use of drugs to combat anemia in cancer patients.
MIT finds genetic clue to bone and fat production
MIT researchers have identified a gene that helps control the balance between bone and fat in the human body, a discovery that could pave the way for the prevention of childhood obesity and the treatment of osteoporosis.
Researchers identify the brain circuits that control hunger
Researchers at UCLA have identified the brain circuits involved in hunger that are influenced by the hormone leptin, the signaling molecule produced by fat cells. In clinical trials, leptin supplementation has produced moderate weight loss in some obese patients by inhibiting hunger and promoting feelings of satiety. The new findings suggest possible new therapeutic targets for obesity, an increasing problem in both adults and children.
Residual fetal cells in women may provide protection against breast cancer
Fetal cells that persist in a woman’s body long after pregnancy – a common occurrence known in scientific circles as fetal microchimerism – in some cases may reduce the woman’s risk of breast cancer, according to researchers at Fred Hutchinson Cancer Research Center. The findings, published in the Oct. 1 issue of
Cancer Research, add to the Jekyll and Hyde characteristics of fetal microchimerism, or FMc, which has been found to be both detrimental and beneficial to women’s health.